NAD+ and the longevity hype, sorted

There is a man at every dinner party now who has done the drip. He mentions it the way people used to mention their trainer — apropos of nothing, twice, before the entrées arrive. Six hundred dollars, a bag on a pole, a Tuesday afternoon he describes as transformative. He looks exactly the same as he did last summer in Provincetown, which he offers as proof that it is working, because imagine how he would look otherwise.

He is not wrong that NAD+ matters. He is wrong about nearly everything after that. So let us sort the molecule from the marketing, because the science is genuinely interesting and the hype is genuinely exhausting, and the two have been sharing a bed for a while now.

What actually declines

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme your cells cannot run without. It shuttles electrons through energy metabolism, it feeds the enzymes that repair DNA, and it fuels the sirtuins that everyone name-drops and few can define. It is not exotic. It is in every cell you own, doing unglamorous work at enormous scale.

And it drifts down as you age. Across multiple human and animal tissues, NAD+ availability falls over the decades, and the enzymes that consume it get busier as cellular wear accumulates. That decline is real, it is measurable, and it is the entire reason this category exists. Which is exactly why the marketing skips straight from "levels fall" to "so replace them and stay young." That leap is where the honesty tends to go missing.

What raising it actually does, and does not

Here is the part the drip evangelist gets half right. You can raise circulating NAD+ by feeding the body a precursor — nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) — that your cells convert into the finished molecule. This is the one slide from his monologue that survives contact with an actual study. In a randomized, double-blind, placebo-controlled trial of healthy overweight adults, daily NR raised whole-blood NAD+ dose-dependently: roughly 22%, 51%, and 142% at 100, 300, and 1000 mg over about two weeks, and the increase held for the rest of the study [1]. The number goes up. It really does go up. That part he can keep.

Now the cold water. Raising a number in your blood is not the same as changing something you can feel. When you step back from the "NAD+ went up" studies and ask the harder question — did anything downstream actually improve, the endpoints a person would care about, strength, stamina, metabolic markers, cognition — the human evidence gets thin, mixed, and early. A systematic review of NAD-boosting across clinical conditions found clear biological activity but concluded that clinical effectiveness remains, at best, unsettled [2]. Translated out of journal-speak: the molecule moves, the outcomes mostly have not, yet.

It helps to understand why the gap exists. A number rising in a blood draw tells you the precursor was absorbed and converted somewhere; it does not tell you the NAD+ reached the specific tissues you were hoping to service, in the amounts those tissues use, at the moments they use them. Whole-blood NAD+ is a receipt, not proof of delivery. Add the ordinary human tendency to feel sharper after spending money and attention on yourself, and you have a category almost engineered to produce glowing anecdotes well ahead of glowing data. None of that makes the mechanism fake. It makes the testimonials weak evidence, which is a different thing.

That is not a reason to sneer. It is a reason to be precise. NAD+ precursors are a promising, well-tolerated intervention with a clean safety record and honest mechanistic logic behind them. They are also not a longevity cheat code, and anyone selling them as one is describing a study that has not been run. The adult position is to take the maintenance case seriously and leave the fairy tale in the pamphlet.

The heart is where the unglamorous money sits

If cellular energy is the theme, the tissue that never gets a day off is the one worth naming out loud. Coenzyme Q10 lives in the mitochondrial machinery that produces energy, and it is especially concentrated where energy demand never lets up. Like NAD+, endogenous CoQ10 tends to decline with age.

The trial literature here is more measured than the internet. Meta-analyses of randomized trials have associated CoQ10 supplementation with improved vascular endothelial function — specifically flow-mediated dilation, a mechanistic readout of how well the lining of your vessels relaxes and responds [3]. That is a maintenance signal, not a rescue, and it is the right altitude to think at: supporting the everyday function of a system you would like to keep boring for as long as possible. No drama, no drip, no dinner-party monologue required.

The honest version

One practical note, since precision is the whole point here. If you are going to run a precursor, treat it as a multi-year, low-drama input and judge it by your bloodwork and your clinician, not by how you feel on a given Thursday. The felt-difference standard is exactly the one this category cannot reliably meet yet, and holding it to that standard is how people talk themselves into a supplement in January and out of it by March, having learned nothing either time.

So, sorted. NAD+ falls with age — true. Precursors raise it, reliably and dose-dependently — also true. The clinical payoff you would actually notice is early, modest, and still being worked out — true, and the part the six-hundred-dollar bag conveniently omits. If you take a precursor, take it as cellular maintenance with plausible mechanism and unproven glory, not as an insurance policy against time. The body is not disposable, but it is also not fooled by a hopeful bag on a pole. Keep the expectations calibrated and the receipts small.

Sources

1. Conze D, Brenner C, Kruger CL. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Scientific Reports, 2019. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611812/
2. Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review. American Journal of Physiology-Endocrinology and Metabolism, 2023. https://journals.physiology.org/doi/full/10.1152/ajpendo.00242.2023
3. Effect of Coenzyme Q10 Supplementation on Vascular Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. High Blood Pressure & Cardiovascular Prevention, 2024. https://link.springer.com/article/10.1007/s40292-024-00630-8

Raising a number in your blood is not the same as changing something you can feel.